Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
University of Giessen
Gruppo Italiano Malattie EMatologiche dell'Adulto
University of Minnesota